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ABSTRACT 
 
BACKGROUND  
The link between tuberculosis (TB) and diabetes mellitus (DM) 
has occupied the centre stage of discussion. Experts have raised concern 
about the merging epidemics of tuberculosis and diabetes particularly in 
the low to medium income countries like India and China that have the 
highest burden of TB in the world, and are experiencing the fastest 
increase in the prevalence of DM. The huge prevalence of DM in India, 
may be contributing to the increasing prevalence of TB. We discuss the 
epidemiology, clinical features, microbiology and radiology, and 
management and treatment outcomes of patients with tuberculosis and 
diabetes mellitus. 
METHOD 
Data were collected from 100 patients with sputum positive 
tuberculosis and were screened for presence of diabetes. Detailed history, 
chestX-rayand sputum analysis were done and patients were followed up 
until treatment 
 
 
RESULTS 
There was male  preponderance  and the mean  age group among  
diabetics patients were 51.5 ± 9 years compared to 34.2 ±7 .26 years. 
Diabetic  patients had  more of chest pain, hemoptysis and dyspnoea  
compared to non-diabetics. Diabetic  patients  had  more sputum 
positivity rates compared to non-diabetics.38 % of the diabetic patients 
had cavities in chest x-ray compared to 20 % amount non diabetics.48 % 
of the diabetic patients  had lower zone  infiltrates compared to 20 % in 
non-diabetics. Sputum conversion rates were84% in non-diabetic TB 
patients  when  compared to 70%  in diabetic  TB patients. Failure rates 
were high as 4% in diabetic patients but not statistically significant 
CONCLUSION 
All  patients  with  pulmonary  tuberculosis  should  be  screened  
for  diabetes  mellitus   and  should   be  effectively  treated  for  the  
same. Pulmonary  Tuberculosis  patients   who  have  diabetes  tend  to  
have higher  sputum  positivity  rates  and  delayed   sputum  conversion  
if  glycemic  levels  are  poorly controlled.. Chest  radiographs  of  such  
patients  show  multiple  cavitations  with  predominant  lower  lobe  
involvement. The  rates  of  treatment  failures   and  treatment  outcomes  
are   adversely   affected   by  the  presence  of  diabetes. 
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INTRODUCTION 
The incidence of diabetes mellitus is on a rise in Indiawith an 
estimated 124 million to be affected by 2030.India tops the list in 
TBburden with 28 % of  the  global  incidence  in  2016.From the 
beginning of 20th centurythe bidirectional association of  diabetes mellitus 
and tuberculosis has been a focus of interest1.Diabetes can affect the 
clinical presentation and outcomes  of  tuberculosis  and  vice  versa .In a 
developing and resource poor country likeIndia the steady increase 
inprevalence of  diabetes has worsened the picture of tuberculosis. This 
comorbidity has become an alarming concern for treating clinicians. 
Active tuberculosis and also latent tuberculosis infection  have 
been known as a risk since long in diabetics. Recent studies have shown 
3-5 times higher risk in acquiring tuberculosis for diabetic patients 
compared to non diabetics2. Subclinical diabetics surface due to stress of 
reigning infection. Tuberculosis also worsens the glycaemiccontrol .It  
reduces the efficacy of management of diabetes mellitus.3 
The emerging epidemic of tuberculosis and diabetes mellitus 
has many impacts. Due to co existence of diabetes or underlying 
hyperglycaemiaalters the clinical presentation of tuberculosis. Patients 
may not be having the classical presentation of cough and breathlessness 
and hence may be an early diagnosis will be missed. For centuries 
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tuberculosis have been known to affect the lung apices due to a 
ventilation perfusion mismatch. In patient with hyperglycaemia ,an 
atypical in volvement of predominantly lower lung fields may confuse the 
physician in making diagnosis. The development of complications related 
to the tuberculosis and its treatment is worse in diabetic compared to non-
diabetics. The sputum conversion is also delayed with lower rates of 
conversion in diabetic patients compared to non diabetics.4-6 
The need to understand the dynamics of the emerging 
epidemic of tuberculosis and diabetes is more than ever. A better 
understanding will lead to early diagnosis, treatment and delay 
complications. 
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AIMS  AND  OBJECTIVES 
 
 To  screen  the  newly  diagnosed  tuberculosis   patients  registered  
under  RNTCP  for  diabetes  mellitus   in  GMKMCH  SALEM  
during year  2016-2017  
 Compare  the  measures  of  TB  severity  at  clinical  presentation  
( including  lung  cavitatory   disease ,  sputum  smear  grade ,  and 
hemoptysis )  in  patients  with  and  without  DM. 
 To  note  the  response  to  treatment  of  Pulmonary  Tuberculosis  
in  diabetes  with  respect  to  sputum  conversion. 
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TUBERCULOSIS  : AN  OVERVIEW 
 
Background : Tuberculosis  remains  a  leading  cause  of  death  
globally . In 2014  there  were  an  estimated  12.8  million   new cases  of  
tuberculosis worldwide7. Incidence  of  tuberculosis  is  greatest  among  
those  with  conditions  impairing  immunity  such  as  HIV  infection  
and  diabetes.8 
History : Many  terms  were  used  to refer  TB  throughout  history-
consumption , phthisis , white plague ,Potts disease . Tuberculosis  is  
caused   by Mycobacteria. They  are  slender  rods .Myco bacteria  means  
fungus  like bacteria. As  they  have  filamentous  branching  forms. In  
this  genus  the  first  member  to  be  identified  was  by  Hansen. It  was  
lepra  bacillus  in  1868.In  1882  the  mammalian  tubercle  bacilli  was  
isolated  by  Koch. He  put  forward  the  Koch’s  postulates. He  made  
the  result  public  on  24th  march  1882  and  hence  the  day  is  called  
world  tuberculosis  day .A  purified  protein  derivative  of  the  bacteria  
called  tuberculin  was  developed  by  Koch  in  1890.Till  this  day  we  
are  using  tuberculin  for  immunisation  against  the  disease. In  1908  
another  breakthrough  discovery  was  made  by Charles  Mantoux.He  
developed  intradermal  test  using  tuberculin  protein   for  diagnosing  
the  disease. 
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Figure 1 :  
A) Robert  Koch discovered  TB bacilli 
B) Mycobacteria tuberculosis under electron  microscope 
Morphology : M .tuberculosis  are  straight  or  curved  rods. They  occur  
singly ,in  pair  or  rarely  clumps. They  are  acid  fast  organisms  due  to  
presence  of   mycolic  acids. The  most  common  medium  used  for  
culture  is  Lowenstein Jenson  medium. It  is  a  solid  medium. It  is  
recommended  by  IUAT.It  contains  coagulated  hens  egg ,mineral  salt  
solution, asparagine  and  malachite  green. Malachite  green  acts  as   
selective  inhibiting  agent. Liquid medium  is  used  for  testing  
sensitivity ,chemical  analysis,. It  is  also  used  for  preparation  of  
vaccines  and  antigens. Liquid  mediums  are  rarely  used for  cultures. 
A B 
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Mode of transmission : An  infected  host  expels  tiny  aerosolised  
droplets  of  infected  material  into air. Infected  material  can  be  saliva 
,sputum  or  phlegm. When  an  individual  inhales  this  transmission  of  
bacteria  occurs. Now   there  are  3  possibilities  for  an  individual  who  
has  acquired  the  bacteria. Either  no  disease  state  develops  or  latent  
TB  or  active  TB  infection  ensues . 
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PATHOGENESIS : 
After   uptake  of  the  bacilli  by  the  host  ,a fraction  reaches  
alveoli  after  evading  upper  respiratory  tract  and  ciliated  mucosal  
cells  .Inactivated  macrophages   ingest  the   bacilli. Macrophage  cell  
surface receptors  are  mannose  receptors, complement   receptors, 
immunoglobulin  binding  GFcy  receptors  and  type   A  scavenger  
receptors. They  help  in  adhering  to  the bacilli  cell  wall. Complement  
activation  occurs.C3b  opsonises  the  bacilli  and  phagocytosis  is  
enhanced. Survival  of  the  bacilli  inside  phagosome  is  dependent  on  
reduced  acidification  this  is  due  to  lack of vesicular –
ATP..Lipoarabino mannan  inhibits  the  release  of  calcium   inside   the  
cell.Lipoarabinomannan  is  a  complex glycolipid, which  is  a  part  of  
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bacilli  cell  wall . Hence  calcium/calmodulin  pathway  comes  to  a  
standstill. It  further  also  inhibits  the  PIP.PIP  marks  the bacilli  
phagosome  for maturation  ,membrane sorting and  phagolysome  
formation. Bacteria also  decelerates  autophagy. Once  phagosome   
maturation  is  stopped, bacilli   will replicate inside  profusely. Finally  
the  phagosome  will rupture  and  bacteria  are  released. Recruitment   of  
other  uninfected  macrophages  occurs.The infectious  cycle  is  further  
continued  and  infection  expands. 
A  specific  virulence  mechanism  is used  by the Mycobacterium  
tuberculosis  to  evade  host  defences. It  also  elicits  early  pro  
inflammatory reaction   which  in turn  leads  to  granuloma  formation. 
The epithelial cells  that  in  contact  with  infected  macrophages  secrete  
MMP9.MMP(Matrix  metallo  proteinase) secretion  is  induced  by  
ESAT-6, a  mycobacterial  protein.MMP9  helps  in  granuloma  
maturation  and  bacterial  growth. Bacterial  growth  can  be  disrupted  
by  inhibiting  MMP9.There  is  an  increase  c-AMP,TNF- alpha and  
other  chemoattractants.Their  increase  help  the  dendritic  cells  to  
catch  the bacilli. They  migrate  to  all  the  draining  lymph  nodes.T-
lymphocytes  are presented  with  mycobacterial  antigens. Then  cell 
mediated immunity and humoral immunity comes into play. During  
these  initial stages host is asymptomatic. 
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Two  host  responses  start  developing  after  2-4  weeks  of  the  
infection. A tissue damaging response and a macrophage activated  cell 
mediated  response. The  mycobacterial  antigens   induce  a  delayed  
hypersensitivity  reaction   resulting  tissue  damaging response cells  
activate  macrophages  which  in  turn  kill  tubercle  bacilli. Both  
mechanisms  are  essential  in inhibiting  bacterial  growth. An  
equilibrium  between  these  two response determines  the  outcome  of  
the  disease. 
 
Figure 2:  Pathogenesis  of tuberculosis 
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Granulomatous  tubercles  develop  in   the  area  of  primary  
lesion. This  is  due  to specific immunity  and  accumulation  of  
activated   macrophages. Granulomas  consist  of  lymphocytes  and 
activated  macrophages. These  later  progress  into  giant cells  and  
epitheloid  cells. Tissue  damaging response kills inactivated 
macrophages and bacilli. It  also  causes  caseating  necrosis  in the centre  
of  the  tubercle. Low  oxygen  tension  and   low  pH  inside  the  
necrotic  milieu  deters  the  growth  bacilli. Some lesions heal by 
fibrosis. Other  lesion   develop  inflammation  and  necrosis. 
Subsequently   calcification   occurs.  
Macrophage activating response :macrophages  process  
mycobacterial  antigens. They  stimulate   T lymphocytes.T lymphocytes  
release  lymphokines.And  local  macrophages  are  activated. Activated  
,macrophages  ensemble  in the  centre  of  the  lesion. They  defuse  
tubercle  bacilli. Further  tissue  destruction  is not  propagated.Caseous  
necrotic  material  is  seen  in  the  centre  of  the  lesion. In  healed  
lesions,  viable  bacteria   may remain  dormant for  many years. It  is  
mainly  seen  inside  macrophages  and  necrotic  material. Healed  
lesions  later  undergo  calcification. 
Delayed  type  hypersensitivity: Cell  mediated  immunity  is 
sometimes  weak. So body  relies  on intensified  DTH  reactions. Such  
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reactions  result  in  tissue  destruction. Lesion  will  propagate. 
Surrounding  tissue  is  destroyed. Necrotic  centre  will  liquefy. 
Surrounding  structures  like  bronchial wall, vessels  are  destroyed. 
Cavities  are  formed. Cavities  and  bronchi  contain liquefied  caseous  
material. Bacteria  multiply  in  these  cavities. Infected  material  spill  
out  into  airways. During  coughing  and  talking  it gets expelled  into  
environment. The  bacilli  migrate  into  central  venous  return  from  
draining  lymph  nodes. They  reinfect  lungs  and  extrapulmonary   
vasculature. Children  have  poor  natural  immunity. They  develop  
disseminated infection resulting in military  TB  and  TB  meningitis. 
Clinical features : Of  all  type  of  infection  pulmonary  TB  is  of  
public  importance. Before  the HIV era, most  of  the  TB  was  
pulmonary. Now  there  is  a drastic change  in  scenario. 
Pulmonary TB :There  are mainly 2 types – primary and post primary 
Primary disease : There  is  formation  of  primary  complex. It is  also  
known as  ghons  complex. It  is  sub  pleural  in location  and  mostly  
seen in  lower part of  upper  lobe  or  upper part  of  lower  lobe. There  
is  associated enlarged  lymphnodes.More  than  70%  of  the  cases  heal 
spontaneously. Any  form  of  immunosuppression  may  lead  to  
progressive  disease. Clinical features  may  be  acute  or  
insidious.Fever,loss of appetite and  weight,  hemoptysis  , chest  pain ,  
12 
 
cough  are  the  main  symptoms. Allergic  manifestations  like  phlycten 
and  erythema  nodosum  may  be  seen  in  some  patienst.Pleural 
effusion   may  be  present  or  tuberculous pneumonia  is  seen. Physical  
examination  may  give  clues  of    collapse, consolidation  or  cavity. 
Post  Primary Disease : There  may  be  direct progression  of  primary  
lesion or  reactivation  of  a dormant foci. Rarely  haematogenous  spread  
or reinfection  can  also  occur. Upper lobes  are commonly  affected. 
There is  early  cavitation,  fibrosis  and  healing. Patients  who  have  
resistance have a slow  developing  nodular  form. If  resistance is  low  a 
fibrocaseous  cavity  type  disease  is  seen. The  initial  lesion  is  usually  
exudative  pneumonia. Blood  vessels  may  become  thrombosed,  
aneurysmal  and  eventually  rupture  to  produce  hemoptysis.Patients  
have  cough,   evening  rise in  temperature,hemoptysis,chest pain  
breathlessness. Sputum  is  mucoid  or  mucoprulent.It  is  initially  scanty  
and  later  copious. Patient  becomes  emaciated  as  disease  progresses. 
On  examination  evidence of cavity,consolidations,effusions   or  
pneumothorax  is  seen. 
Complications : 
                 Early  complications  include hemoptysis, pneumothorax, 
pleural  effusion  and  poncet  syndrome. Intermediate  complications  
include    secondary  infection  of  cavities, massive  hemoptysis, 
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progressive  fibrosis, hemotogenous  spread  and  non healing  lesions. 
Late  complications  include  bronchiectasis,  fibrosis,  aspergilloma, 
carcinoma and  secondary  amyloidosis. 
INVESTIGATIONS 
Sputum  examination : the  bacilli  are demonstrated  by Ziehl Nelson  
staining  method. The  amount  of  bacilli in sputum  will affect  the 
positivity  of  smears  and  cultures.100fields  are examined  for  10 mins  
before declaring  it negative. Now  PCR  and  CBNAAT  studies  are  
available which is more rapid  and cost  effective. Further  confirmation  
is  obtained  by  using  cultures. Early  morning  sputum samples  are 
preferred  for  smear  examinations. 
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Figure 3 : Grading  of smears for  acid fast bacilli 
Radiology : It is the  most  easiest and readily available  diagnostic  
test.Primary  Tb  can affect  upper and  middle lobes. Progressive  disease  
are seen in  upper  lobes with  cavitatory  lesions. Cavities  are often thin 
walled, multiple and with  intervening  fibrosis. Bilateral  lesions  are  
almost  always  suggestive  of  tuberculosis. Once cavitation and fibrosis  
has  set in  lesion  may not heal  with  treatment. In the long course  there  
may  be evidence  of  fibrosis, collapse  and  destroyed  lung. 
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Figure 4 : Chest  radiograph  of  patient  showing  upper  lobe  
involvement with cavity 
BLOOD  INVESTIGATIONS : These  include  routine 
investigations.PCR  testing  is  useful  as  it  is  highly  sensitive and 
specific. Interferon  release  assays  are  taking  an important role  in 
diagnosing  TB  these  days  
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Figure 5 : Diagnostic  Algorithm For Pulmonary TB 
 
TREATMENT 
The  goals  of  treatment  include   ensuring  cure without  relapse, 
to prevent death, to  prevent  spread  and  to  prevent  development of  
resistance. Treatment  consists  of  an  active  phase or intensive  phase  
where  all  actively  growing  bacilli  are  killed. Also  a  proportion  of  
dormant  organisms  are  also  killed. In  continuation  phase  the 
remaining  persisting  bacilli are  eliminated 
Adequate  chemotherapy  administered  without  interruption  is  
the  cornerstone  of  success. 
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Figure 6 Recommended doses  of anti Tuberculosis drugs 
TABLE A 
 
TABLE B 
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TABLE 1 : TABLE SHOWING  TREATMENT CATEGORIES IN TB 
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DIABETES  MELLITUS 
Background  
Diabetes  mellitus  is a chronic disorder of metabolism. Chronic  
hyperglycaemia with or without glycosuria  secondary to defects insulin 
secretion, action or resistance to insulin. There is disturbance of 
carbohydrate, protein and fat metabolism. It leads to both microvascular 
and macrovascular complications. Retinopathy with progressive 
blindness,neuropathy,neuropathy with renal failure, autonomic 
dysfunction and Charcot   joints  are micro vascular complications. 
Cerebrovacsular,peripheral occlusive vascular disease and cardiovascular 
disease are macrovascular  disease. 
History :In  1500  B.C    the  first  mention  of  diabetes  as  a  
condition  causing  polyuria  was  first  made in  Papyrus Ebers  at Luxor 
in Egypt. The word  diabetes  was  first  used  by  Aretaeus   of  
Cappadocia   in  the  second   century  AD.It  comes   from  the  Greek  
word  meaning  Siphon. 
Prevalence : 
Diabetes  Mellitus  is  an  epidemic  disease  seen throughout   the 
world. It is more  observed  in developed countries. By 2030, the  major  
burden  will be  shared  by Asian and  African  countries. In 
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2014,according  to ICMR there are 73.4  million  diabetics  and  86.2  
million  prediabetics  in India. The  prevalence is estimated to be  366  
million worldwide by 2030.India  will  be having one third of the disease 
burden. Type 2 Diabetes  mellitus  amongst  Indians occur a decade 
earlier when compared to western population. Indians have more  
abdominal obesity and waist hip ratio. Also  urbanisation  and  changing   
lifestyle  adds  to it.   
Classification of diabetes 
In 1979a uniform terminology and a functional classification of 
diabetes was developed. It classifies  diabetes into insulin  dependent 
diabetes  and non insulin dependent diabetes by the  National  Diabetic 
Data Group  in USA.Modifications were later made by Who expert 
committee in 1980 and 1985.An International  Expert  Committee 
,working under the sponsorship of ADA  proposed the current 
classification and diagnostic criteria in 1997.This  was  later accepted by  
WHO. 
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Figure 7 : ETIOLOGICAL CLASSIFICATION OF DIABETES 
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DIABETES MELLITUS  DIAGNOSIS 
The American  Diabetes  Association criteria for the diagnosis of 
diabetes are the following for non pregnant patients 
TABLE 2 : ADA DIAGNOSTIC CRITERIA FOR DIABETES 
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Diabetes mellitus type 1 
It occurs due to absolute insulin deficiency. Positive family 
history is rare and ketonuria is common. The patients are dependent on 
exogenous insulin for metabolic control and survival. 
It  develops in people who are genetically predisposed. In addition 
the certain environmental triggers start the process of autoimmune 
destruction leading to complete beta cell destruction and insulopaenia. 
Type 1 diabetes is associated with autoimmune antibodies. 
Markers of beta cell destruction include islet cellantibodies, antibodies to 
insulin, antibodies to GAD, antibodies to tyrosine phosphatase IA-2 and 
IA-2 B.It is presenting 80-90 % of the individuals. 
The rate of  beta cell  destruction is variable  is  some individuals. 
Some have a  rapid course like infants and children. Adults usually have a  
slow  course. Diabetic  ketoacidosis can  be the first presentation in many  
patients especially children. These patients  are at higher risk  of 
developing other autoimmune diseases . 
Diabetes Mellitus type 2 
This type of diabetes , which accounts for 90% of patients is seen 
middle aged people but can occur in children and early adulthood also. It 
was  previously referred to as non insulin dependent or adult onset 
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diabetes. It is caused by interaction of environmental triggers and genetic 
predisposition. It is a polygenic disorder. It is caused by a cluster of 
susceptibility genes. Type 2 diabetes patients have relative insulin 
deficiency secondary to insulin resistance. 
Most of  these patients  are obese or have increased percentage of 
abdominal body fat and a high waist hip ratio. Diabetic ketoacidosis is  
not that common in this type of diabetes. It is usually precipitated by 
stress of another illness, most commonly infections. This type of diabetes 
goes undiagnosed for  many years because the hyperglycemia develops 
gradually and at earlier stages is often not severe enough  for the patient 
to notice the classical symptoms of the disease. Most of these patients 
develop micro vascular and macro vascular complications of the disease. 
Associated with insulin resistance, secretion is also defective to maintain 
metabolic control. Insulin resistance  usually improves with weight 
reduction  and glycemic control, It  is seldom restored to normal. The  
risk of  developing the  disease increases  with  the  age,  obesity  and  
lack  of  physical  activity. It is associated  with dyslipidemia, 
hypertension and women with  prior  GDM. 
GESTATIONAL DIABETES MELLITUS 
Glucose intolerance that develops during  pregnancy  and 
typically  resolves  with  delivery, occurs  in  about  7 % of all  
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pregnancies. This occurs due to insulin resistance in pregnancy, 
overweight, obesity and genetic predisposition. 
DIABETES MELLITUS SYMPTOMS. 
The symptoms of uncontrolled diabetes are related to high blood 
glucose levels and loss of sugar in urine. Glycosuria causes increased 
urination leading to dehydration. It leads to increased thirst and increase 
in appetite. These patients  have abrupt onset signs and symptoms of 
hyperglycemia.The inability to utilise  glucose energy eventually  leads to 
weight loss. Patients have polyuria, polydipsia ,polyphagia, weight loss 
and fatigue. Elevated glucose levels leads to lethargy and coma. Patients 
can develop diabetic ketoacidosis or  hyperosmolar coma. They can 
develop symptoms of microvascular and macrovascular complications. 
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ASSOCIATION  OF  TUBERCULOSIS  AND  DIABETES  
MELLITUS 
From  the  initial  part  of  the  20th  century ,an  association  
between tuberculosis and diabetes  have  been noted  by treating  
physicians.It  was  unclear  at that  point whether  TB  caused  diabetes  
or  whether  diabetes  caused TB.  The   coming  decades  showed  
clinicians  taking  active  interest  in this  associations  and  studies  being  
published  about  this  emerging  coepidemic.9-13 
The  last  decade  saw  multiple  observational  studies  been done  
on this coexistence  and the  association  being  proven  beyond doubt.14-
18McCornick  and   colleagues  from  the  University  of  Texas  school  of  
Public  Health did a study  in  2007 .They  surveyed  the  link  between  
the  two diseases .It was done  in  over  6000  TB  patients  on  the  two  
sides  of  the  Rio  Grande  River. Using  this  retrospective  data  they  
established  that  the  co morbidity of  TB-DM  exceeded  that  of  TB-
HIV. These  patients  were  older. They  had  more  chance  of  
developing  hemoptysis  and  chest  cavities. They  tend  to  be  smear  
positive  at  diagnosis. They   remain  positive  at  the  end  of  the  first  
and  second  month  of  treatment. 
In  Mexicans  and  Hispanic  Americans  diabetes  was  found  to   
be  an  important  risk  factors. These  links  raised  concerns  regarding  
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public health. There  is  likely   immunological  impairment  in  M.Th.  
significance  of  diabetic  control  in  tuberculosis  and  incidence  of 
infection  in diabetes  was of concern.  
The   public  health  significance  of TB-DM  comorbidity is 
high.TB   is  a leading  killer  in the developing  countries  and India  has  
become  the global  capital  for  diabetes  mellitus. Thus  a systematic  
assessment  of this  coepidemic  is  absolutely  necessary to  combat  the  
diseases  and  stratify  the  situation. 
A  recent  journal  in  BMC  cited  that   much of the tuberculosis 
burden  in  India  can  be  accredited  to  diabetes. As  much  as  15.8%  
of  pulmonary  tuberculosis  and  21.2%  of  smear-positive  i.e.  
infectious tuberculosis  is linked  to this disease19. The  scenario  of   
tuberculosis  is changing  with  an  urban  preponderance   probably due  
to  diabetes  when  compared  to  rural  areas20. But  poverty  is  an  
independent  risk  for  TB. Patients  in  rural  areas  have   delayed  
diagnosis  of  this  coepidemic. 
In  India  in  2010, there  were  an  estimated  487,573,000  people 
over  the  age  of  20  years21. Among  these , 5.3%  i.e. around  
21,707,639  had diabetes .949,064  developed  pulmonary  tuberculosis. 
575,900  were  smear-positive  and  infectious. The  recent  studies  
predict  that  in  India 17.4% (12.5% to 29.9%)  of  people  with  
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pulmonary  tuberculosis (both smear-positive and smear-negative) have  
diabetes  .23.5% (12.1% to 44%)  of  patients  in smear  positive  group  
has  diabetes22. 
Once  acquiring  tubercle  bacilli  any  person  has a 10 %  chance  
of  acquiring  infection  in  his  lifetime. There   is  5% chance in the first  
2  years  and another  5%  chance  in  the  entire  lifetime. Impaired  
glucose  tolerance  has  been  detected  in  TB   patients  for  a  very  long  
time22. This  is  due to the  increase  in  stress hormones  ,insulin  
resistance  and  also  rarely  tuberculosis  of the  pancreas.  Different 
studies  uses  different  diagnostic  criteria  and  hence  comparisons  are  
difficult. Around  half  of  these  patients  return  back  to normal  glucose  
levels  on  completion  of  anti tuberculosis  treatment.  
At present  one  third  of the population is affected  with  latent  
tuberculosis. To  contain  the  infection  is  a challenge. With  increasing 
prevalence  of  diabetes  the amount  of patients  developing  active  
disease  is going  to be  high. India  has  very  few  studies  on  the risk  
factors  associated with  tuberculosis. Sikand  and  Parma carried  out 
study in 1949.The  incidence  of  tuberculosis  in  silicosis  patients  was  
24.9 %23 
Multiple  theories  have  been put  forward  regarding  the 
association of TB and  DM. Hyper glycemia  favours  growth, 
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survival,viability  and  propagation  of  mycobacteria22. Increased  
glucose  levels  augments  chance  of  infections  and  decreases  the  
repair capacity  of  cells. There  is  electrolyte  imbalance  with  local  
tissue  acidosis. Certain  study  suggest   that  there  is  lowering  of  
protective  cytological  function. Also  presence  of glycerol  and  
nitrogenous  waste  products  aids  in  growth  of  bacilli24. 
The  possibility of  pituitary  dysfunction  is  being  validated. 
There  is  increased  production  of  ACTH  leading to  increased  
corticosteroids. Reduced  defense  mechanisms   leads  to  exudative  
inflammation  and  less  of  granulation  tissue. There   is  increased  
insulin resistance25. Hepatic  dysfunction   and  ensuing   hypovitaminosis  
of  A  and D  may  result  in    pulmonary involvement  more  than  
extrapulmonary  involvement  in  diabetes. 
There   is  decreased  production  of  Th1  mediated  cytokines  and  
gamma interferons26.The  cytokines  in  diabetic  people  has  reduced   
chemo taxis  and less leucocyte bactericidal  activity. There  is  decreased  
production  of  IL-2 , TNF  and  monocytes  in  blood27. The decrease  in  
function  is  directly  proportional to blood sugar    and  glycated  
haemoglobin  levels. 
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CLINICAL  FEATURES 
Diabetic  patients  tend  to have  an aggressive  course  of disease28. 
The  latent  Tb  is activated  more. Patients  are  usually  elderly  and  
male. Experienced  clinicians  observe  that  patients  with  both  diabetes  
and tuberculosis  usually  have  a  prolonged  duration  of  fever  and  
more  significant  weight  loss  with  co-existent  disease  than  with  
diabetes  or  pulmonary  tuberculosis  alone. Patients   have  prolonged  
fever ,weight loss ,hemoptysis  and  chest  pain30-31. Any diabetic  patients  
presenting  with  such  symptoms  should  be evaluated  for  TB.  Also   
all   tuberculosis  patients  should  undergo  diabetic  screening. 
Large  number  of studies  has  been  made  in radiological  
profiling of  pulmonary  tuberculosis patients  with  diabetes. Most  of  
the clinicians  find the  findings  atypical. There  is  involvement  of 
lower  lung  fields  and  also  evidence  of  multiple  cavitations   in  most  
of  the  studies32. Lower  lobe  involvement  with  coexisting  cavitations  
should  raise  the  suspicion  of  TB-DM  disease. 
There  is  5  to  6  higher   risk  of  developing  sputum  positive  
pulmonary  TB  in  diabetics33. Sputum  conversion  and  smear  
positivity  are  methods  to  monitor  to effective  treatment. Patients    
with  diabetes, radio logically   extensive  disease  and  cavities  are  
delayed  sputum  conversion. Diabetes  is  considered  an  independent  
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risk  factor  for  this. Also  the   amount  of  bacilli in  oil  immersion field  
is  directly  proportional  to  the  blood  glucose  levels34. The  
suppression  of  immune  system  by diabetes  may  cause  this  high  pre 
treatment  bacillary  load. 
The  mortality  rates  were high  in  diabetic  patients  with  
pulmonary  tuberculosis  when  compared  to  non diabetic. Failures, 
relapserates  and  death  were  more  seen in diabetes32. Although  there  
are  studies  that  show  that  diabetes do  not alter the  outcomes  of  
treatment  in TB  patients. Diabetic  patient  were  more  to develop  drug  
resistance  tuberculosis. There is  8-9  times  of  risk  of  developing  
multi drug  resistance  tuberculosis35. This  is  mainly  attributed  to  the   
hyperglycemia  causing  reduced  drug  absorption due  to gastric  
paresis36. It  also  leads  to impaired  alveolar  macrophage  function  and   
altered   CD 4 function. 
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REVIEW   OF   PREVIOUS   STUDIES 
A  multicentre  case-control  study  was  conducted  in  Guinee, 
Guinea  Bissau  and  Gambia  in  West  Africa. It  was  from  January  
1999  to March  2001. 846  newly  detected  sputum  smear  positive  
cases , 702 household  controls  and  828  community  controls  were  
recruited  in  the  three  countries. It  showed   that  most  of  the patients   
were  male,  smokers  and  diabetes  was  an  independent  risk  factor  in  
development  of  tuberculosis37. 
Deshmukh  et  al  studied  138  TB-DM  patients .  He  established   
that  82.6%  of the study population was above 45 years of age  with  a 
male preponderance. 43.4% of TB patients gave prior  history of DM. 
56.6% were detected further on the examination of urine  and  confirmed 
by blood sugar examination. Authors observed that, when a known case 
of diabetes presents with symptoms of general ill-health like fever, 
weakness, apathy, cough, haemoptysis, and chest pain; investigations 
may reveal the presence of tuberculosis30. 
Tripathi  et  al  noted  that  TB  patients  with  diabetes  were 
underweight  and  above  the age  of  45  years31. 
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Perenz-Guzman et al  conducted  a  study  on 192  TB-DM  
patients  in Mexico  TB  patients as controls.TB-DM patients were found 
to be older (51.3 ± 0.9 vs. TB group 44.9 ± 1.8 years). They  had a 
decreased frequency of upper (17% vs. 56%), and an  increased  
involvement   of lower (19% vs.7%) and upper and lower (64% vs. 36%) 
lung field lesions.TB-DM patients were   prone   for   cavitations (82% 
vs. 59%) 38.They  most    often involved   lower lung fields (29% vs. 3%). 
Cavities  were  often  multiple in the TB-DM patients (25% vs. 2%).     
The  bacteriological  profile  of   737  patients  were  studied  in  
turkey. These  patients  were   hospitalized  from  2000  to  2005  with  
pulmonary  TB. Three  hundred  six (193 men and 113 women) patients  
with newly  diagnosed   pulmonary  TB  were  studied33.  Factors  
associated  with  both  sputum  smear  and  culture  conversion  time  
were  investigated. Patients  with  DM,  cavitary  disease  and  
radiologically  extensive  disease  had  longer  sputum  smear  and  
culture  conversion  time  when   compared   to   the  other groups. 
692  smear-positive  pulmonary  TB   patients in Riyadh, Saudi 
Arabia,  were   evaluated. The  baseline   characters   of  187  patients  
with  DM (TB-DM group)   and    505 patients without DM (TB group)  
were  compared. 65.2% of the patients in TB-DM  group   had numerous 
(>1 bacillus per oil  
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immersion field)   AFB  on   smear   examination    compared  to  54.1%   
In  a  study  by  Ruslami  et  al  the  incidence  of  Diabetes  and  
tuberculosis  coepidemic  was   highest  in  India   among  10  developing   
nations39.  
Sosman  et  al  studied  the  radiological  profile  of  pulmonary  
tuberculosis  with  diabetes  and  found  that   multilobular  cavitatory  TB   
is  more  common  in  diabetic  people40. 
Wang  et  al  studied  self  reported  symptoms   among  TB  
patients  with  diabetes. He  found  that  such  patients  had  more of  
fever  and  hemoptysis41. 
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MATERIALS AND METHODS 
Study design : 
Prospective  non  interventional  case  control  study  onclinical 
outcomes of sputum positive tuberculosis in newly detected diabetes 
patients in comparison to non diabetic patients. 
Setting : 
The  study  was  carried  at  Government  Mohan  
Kumaramangalam  Medical  College  Hospital,  Salem 
Approval : 
The  study  was  approved  by  ethical committee  of  Government  
Mohan  Kumaramangalam  Medical  College  Hospital,  Salem. 
Study Population: 
100 cases  of  newly  diagnosed  sputum  positive   pulmonary 
tuberculosis( 50  diabetic  and  50  non  diabetic )  fitting the inclusion 
criteria admitted over the period  of  2  years  from  2016-2017.Subjects  
were  selected  from  medicine  ward, pulmonology  ward  and  
Tuberculosis  ward  under  DTC.The  diagnosis  of  Pulmonary  
tuberculosis  was  made with  clinical  presentation  and  verification  by  
detection  of  acid  fast bacilli  under  microscope . 
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Inclusion  Criteria : 
• Age 18-75 Years 
• Newly diagnosed sputum positive pulmonary tuberculosis 
cases. 
Exclusion Criteria : 
• Patients on steroids, thiazide diuretics  
• HIV patients  
• Sputum smear negative Pulmonary tuberculosis cases and extra 
pulmonary tuberculosis  
• Patients not willing to participate. 
• Pregnant women  and  women  in  postpartum  period  less  than  
6 weeks  of  delivery) 
• Multi drug resistance Tuberculosis patients 
• Known case of diabetes mellitus 
Consent : 
Patients  were  informed  about  the deatils  of the  tests  
performed  and  all  investigations  were  collected  with  consent. 
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Measurement  of  glucose  concentration : 
 All  patients  underwent  fasting blood  glucose  testing  at 
initiation of TB treatment. Any  value  above 110 mg/dl  was  considered  
abnormal. A  2 hour sample for  plasma  glucose  was  repeated  after  75 
grams OGTT.Values  above  or equal  to 200 mg/dl  was considered. 
Such  patients  were  included  in diabetic  category. Diabetic  patients  
were  offered  anti-diabetic  medications   at  the  diabetic  clinic 
Collection  of  other  variables : 
Detailed  history  with  respect  to  age ,sex ,risk   factors  like  
smoking , alcohol  and  pan  chewing  were  collected. The symptoms at 
the time of presentation and  Chest  X-Ray   findings  were  recorded. 
Mycobacterial  load  was  assessed  and  sputum  cultures  were  done  at  
2 months  and  at  end  of  treatment. Patients  were  regularly  followed. 
Adverse  drug reactions  were  monitored. Mainly  5  adverse  drug  
reaction  nausea  and  vomiting, peripheralneuropathy, liverinjury, 
hypoglycaemia  and  back  pain  were  monitored. Liver  injury  was  
defined  as  clinical  symptoms  and  signs  of  toxic  hepatitis  or  
elevation  of  enzymes  more  than  3  times  normal.   
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Definition  of  TB  treatment  outcomes 
 
Statistical Methods:  
Clinical presentation, severity, and  treatment  response to 
tuberculosis (sputum conversion at 2 months)  were considered  as  
primary  outcome  variables 
Secondary  outcome variable: ADR (Adverse Drug Reaction) 
(peripheral neuropathy, liver injury, hypoglycemia, back pain, nausea 
vomiting)  
Primary explanatory variable: Diabetic status and glycemic 
control (as assessed by FBS and PPBS)  
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Other relevant variables: Age, gender, risk factors (alcohol, 
smoking, Pan chewing), etc. were considered as other explanatory 
variables.  
Descriptive analysis was carried out by mean and standard 
deviation for quantitative variables, frequency and proportion for 
categorical variables. Data was also represented using appropriate 
diagrams like bar diagram, pie diagram and box plots. 
The association between diabetic status, response to tuberculosis, 
ADR peripheral neuropathy, and quantitative explanatory parameters 
like, FBS, PPBS, sputum positivity, was assessed by comparing the mean 
values. The mean differences along with their 95% CI were presented. 
Independent sample t-test/ ANOVA. 
The association between severity, response to tuberculosis and 
diabetic status was assessed by cross tabulation and comparison of 
percentages with 95% CI is presented. Chi square test was used to test 
statistical significance and represented using appropriate diagrams like 
stacked bar diagram 
P value< 0.05 was considered statistically significant. IBM SPSS 
version 22 was used for statistical analysis.(1) 
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OBSERVATION  AND  RESULTS 
The  results  of  the  study  are as  follows 
A  total  of  100  subjects  were  included  in  final  analysis. 
Table 3: Descriptive  analysis  of  diabetic  status  in  study  
population (N=100) 
Diabetic  status Frequency Percentage 
Diabetics 50 50.00% 
Non  diabetics 50 50.00% 
 
Among  the  study  population , 50 (50%)  were  diabetics  and  50 (50%)   
were  non-diabetic.  
Table 4: Descriptive  analysis  of  gender  in  study  population 
(N=100)  
SEX Frequency Percentage 
Male 56 56.00% 
Female 44 44.00% 
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Among  the  study  population , 56(56.00%)  were  male  and  
44(44.00%)  were female.  
CHART 1.  :  Pie  chart  showing  sex  distribution
 
TABLE 5 :Frequency  distribution  of  patients  by  age : 
 FREQUENCY PERCENTAGE 
UPTO 20 1 1.0 
21-30 13 13.0 
31-40 28 28.0 
41-50 37 37.0 
51-60 11 11.0 
61-70 8 8.0 
ABOVE 70 2 2.0 
56%
44%
GENDER
MALE
FEMALE
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CHART 2 : Bar  diagram  showing  age  distribution 
 
Table 6: Descriptive  analysis  for  AGE  in  study  population 
(N=100) 
Parameter 
Mean 
±STD 
Median Min Max 
95% C.I. for EXP(B) 
Lower Upper 
AGE 
42.65 
± 
11.76 
42.50 19.00 72.00 40.32 44.98 
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The  mean  age  was  42.65 ± 11.76  in  the  study  population. Minimum  
years was  19  and  maximum  years  was  72  in  the  study  population 
(95% CI 40.32 to 44.98). 
 
Table 7: Comparison  of  mean  AGE  across  study  groups (N=100) 
DIABETIC 
STATUS 
AGE 
Mean± STD 
Mean 
difference 
95% CI P 
value Lower Upper 
Diabetics 51.1 ± 9 
16.90 13.66 20.14 <0.001 
Non diabetics 34.2 ± 7.26 
 
The  mean  age of  diabetic  status  was  51.1 ± 9  and  non-diabetic  was  
34.2 ± 7.26 , and  the  mean  difference  (16.90)  between  two  groups  
was  statistically  significant (P value <0.001). 
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Table 8: Descriptive  analysis  of  risk  factors  in  study  population 
(N=100) 
Parameter Frequency Percent 
Risk  factors  smoking 
Yes 33 33.00% 
No 67 67.00% 
Risk  factors  alcohol 
Yes 38 38.00% 
No 62 62.00% 
Pan  chewing 
Yes 9 9.00% 
No 91 91.00% 
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Chart 3: Horizontal  bar  diagram  showing  risk  factors  in  study  
population 
 
Among  the  study   population  33(33.00%)  were  smokers , 38  
(38.00%) were alcoholics  and  9 (9.00%)  were  habituated  to  pan  
chewing. 
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Table 9: Descriptive analysis of symptoms in study population 
(N=100) 
Parameter Frequency Percent 
Dyspnoea 
Yes 53 53.00% 
No 47 47.00% 
 
Chest Pain 
Yes 41 41.00% 
No 59 59.00% 
Loss of appetite 
Yes 66 66.00% 
No 34 34.00% 
Evening  rise of fever 
Yes 60 60.00% 
No 40 40.00% 
Loss of weight 
Yes 81 81.00% 
No 19 19.00% 
HEMOPTYSIS 
Yes 32 32.00% 
No 68 68.00% 
 
Cough 
Yes 78 78.00% 
No 22 22.00% 
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CHART 4: bar  diagram  showing  distribution  of  symptoms 
 
Among  the  study  population,  53  (53.00%) had  dyspnoea, 41  
(41.00%) had chest  pain,  66(66.00%)  had  loss  of  appetite , 60 
(60.00%)  had  evening  rise of  temperature, 81(81.00%)  had  loss  of  
weight, 32 (32.00%)  had  hemoptysis ,  78 (78.00%)  had  cough. 
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Table 10: Association of diabetic status with dyspnoea of study 
population (N=100) 
Dyspnoea 
DIABETIC STATUS 
Chi 
square 
P-value Diabetics 
(N=50) 
Non 
diabetics(N=50) 
Yes 34 (68%) 19 (38%) 
9.033 0.003 
No 16 (32%) 31 (62%) 
 
Chart 5: horizontal   bar  diagram  showing  dyspnoea  symptom  in  
diabetic  and  non  diabetic  patients. 
 
Among the diabetic, 34 (68%) had dyspnoea. Among the non-diabetic, 19 
(38%) had dyspnoea.The difference in the proportion of diabetic status 
between dyspnoea was statistically significant (P value 0.003)  
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Table 11: Association of diabetic status with chest pain of study 
population (N=100) 
Chest Pain 
DIABETIC STATUS Chi 
square 
P-value 
Diabetics Non diabetics 
Yes 27 (54%) 14 (28%) 
6.986 0.008 
No 23 (46%) 36 (72%) 
 
CHART 6 : Pyramid showing  percentage of chest pain among 
diabetic and non diabetic 
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Among the diabetic, 27 (54%) had chest pain. Among the non-diabetic, 
14 (28%) had chest pain.The difference in the proportion of diabetic 
status between chest pain was statistically significant (P value 0.008)  
Table 12: Association of diabetic status with hemoptysis of study 
population (N=100) 
HEMOPTYSIS 
DIABETIC STATUS Chi 
square 
P-
value Diabetics Non diabetics 
Yes 21 (42%) 11 (22%) 
4.596 0.032 
No 29 (58%) 39 (78%) 
 
CHART 7: horizontal  bar  diagram showing  hemoptysis  in diabetic  
and non  diabetic patients 
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Among the diabetic, 21 (42%) had hemoptysis. Among the non-diabetic, 
11 (22%) had hemoptysis.The difference in the proportion of diabetic 
status between hemoptysis was statistically significant (P value 0.032)  
Table 13: Association of diabetic status with cough of study 
population (N=100) 
COUGH 
DIABETIC STATUS 
Chi square P-value 
Diabetics Non diabetics 
Yes 36 (72%) 42 (84%) 
2.098 0.148 
No 14 (28%) 8 (16%) 
 
Among the diabetic,36 (72%) had cough. Among the non-diabetic,42 
(84%) had cough. The difference in the proportion of diabetic status 
between cough was statistically not significant (P value 0.148)  
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Table 14: Association of diabetic status with loss of weight of study 
population (N=100) 
Loss of weight 
DIABETIC STATUS 
Chi square P-value 
Diabetics Non diabetics 
Yes 39 (78%) 42 (84%) 
0.585 0.444 
No 11 (22%) 8 (16%) 
Among the diabetic, 39 (78%) had loss of weight. Among the non-
diabetic 42 (84%) had loss of weight. The difference in the proportion of 
diabetic status between loss of weight was statistically not significant (P 
value 0.444)  
Table 15: Association of diabetic status with loss of appetite of study 
population (N=100) 
Loss of 
appetite 
DIABETIC STATUS 
Chi square 
P-
value Diabetics 
Non 
diabetics 
Yes 29 (58%) 37 (74%) 
2.852 0.091 
No 21 (42%) 13 (26%) 
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Among the diabetic, 29 (58%) had loos of appetite. Among the non-
diabetic 37 (74%) had loss of appetite. The difference in the proportion of 
diabetic status between loss of appetite was statistically not significant (P 
value 0.091) (Table 46) 
Chart 8: bar diagram showing symptoms analysis in diabetic and 
non diabetic patients 
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Table 16: Descriptive  analysis  of  sputum  positivity  in  study  
population (N=100) 
Sputum positivity Frequency Percentages 
1+ 27 27.00% 
2+ 54 54.00% 
3+ 19 19.00% 
 
 
CHART 9: Doughnut  diagram showing  sputum  positivity  rates  in  
study population 
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Among  the  study  population  of  sputum  positivity  was  1+ , 2+  and  
3+  in  27 (27.00%),  54  (54.00%)  and  19  (19.00%)  subjects  
respectively . 
Table 17: Association of diabetic status with sputum positivity of 
study population (N=100) 
Sputum 
Positivity 
Diabetic Status 
Chi 
square 
P-
value 
Diabetics 
(N=50) 
Non diabetics 
(N=50) 
1+ 6 (12%) 21 (42%) 
13.263 0.001 2+ 30 (60%) 24 (48%) 
3+ 14 (28%) 5 (10%) 
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CHART 10 :  Bar  diagram  showing  sputum  positivity  rates  
among diabetics  and non  diabetics
 
 
Among  the  diabetic , 6  (12%)  had  positivity  1,  30  (60%)  had  
positivity  2 , and  14 (28%)  had  positivity  3.Among  the  non-diabetic , 
21  (42%)  had  positivity  1, 24  (48%)  had  positivity  2,  and  5 (10%)  
had  positivity  3.The  difference  in  the  proportion  of  diabetic  status  
between  sputum  positivity  was  statistically  significant  (P value 
0.001). 
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Table 18: Comparison of mean FBS across study groups (N=100) 
Sputum 
Positivity Mean ± S. D 
Mean 
difference 
95% Confidence 
Interval for 
Mean P 
value 
Lower 
Bound 
Upper 
Bound 
1+ 
102.41 ± 
20.32     
2+ 
137.72 ± 
44.22 
35.315 15.38 55.25 <0.001 
3+ 
178.21 ± 
58.58 
75.803 50.48 101.13 <0.001 
 
CHART 11 :  Diagram  showing  mean  FBS  value  in  each sputum  
positivity groups 
 
The mean FBShad positivity 1 was 102.41 ± 20.32, 137.72 ± 44.22 had 
positivity 2 and 178.21 ± 58.58 had positivity 3. Considering sputum 
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positivity 1 as base line, the mean difference of FBS(35.315) in positivity 
2 was statistically significant (P value <0.001) and also positivity 3 
(75.803) was statistically significant (P value <0.001). 
Table 19: Comparison of mean PPBS across study groups (N=100) 
 
Sputum 
Positivity 
Mean ± S. D 
Mean 
difference 
95% Confidence 
Interval for Mean P 
value Lower 
Bound 
Upper 
Bound 
1+ 
141.11 ± 
40.69     
2+ 
204.04 ± 
80.73 
62.926 26.29 99.56 <0.001 
3+ 
282.16 ± 
107.11 
141.047 94.50 187.59 <0.001 
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CHART 12 : Bar diagram showing mean PPBS value in sputum 
positivity groups 
 
The mean PPBShad positivity 1 was 141.11 ± 40.69, 204.04 ± 80.73 had 
positivity 2 and 282.16 ± 107.11 had positivity 3. Considering sputum 
positivity 1 as base line, the mean difference of PPBS(62.926) in 
positivity 2 was statistically significant (P value <0.001) and also 
positivity 3 (94.50) was statistically significant (P value <0.001).  
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Table 20: Descriptive analysis of Chest x-ray cavity in study 
population (N=100) 
Chest x-ray  cavity Frequency Percentage 
CAVITY 29 29.00% 
NO 66 66.00% 
PLEURAL EFFUSION 3 3.00% 
PNEUMOTHORAX 2 2.00% 
 
CHART 13 : bar diagram showing x ray findings in study population 
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Among the study population, 29(29.00%) had cavity in chest X-ray, 3 
(3.00%) had pleural effusion and 2 (2.00%) had pneumothorax.  
Table 21: Association of diabetic status with Chest X-ray CAVITY of 
study population (N=100) 
 
Chest X-ray 
CAVITY 
DIABETIC STATUS Chi 
squar
e 
P-
valu
e Diabetics(N=50
) 
Non 
diabetics(N=50
) 
CAVITY 19 (38%) 10 (20%)  
3.934 
0.04
7 NO 27 (54%) 39 (78%) 
PLEURAL 
EFFUSION 
2 (4%) 1 (2%) 
  
PNEUMOTHORA
X 
2 (4%) 0 (0%) 
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CHART 14: bar  diagram  showing  chest X ray findings in each 
study group 
 
Among the diabetic, 19 (38%) had cavity, 27 (54%) had no cavity, 2 (4%) 
had pleural effusion, and 2(4%) had pneumothorax. Among the non-
diabetic, 10(20%) had cavity, 39 (78%) had no cavity, 1 (2%) had pleural 
effusion. The difference in the proportion  of diabetic status between 
chest X-ray cavity was statistically significant. 
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Table 22: Descriptive analysis of upper zone infiltrates in study 
population (N=100) 
Upper zone infiltrates Frequency Percentage 
Yes(bilateral) 16 16.00% 
Yes(left) 33 33.00% 
Yes(right) 24 24.00% 
No 27 27.00% 
 
Table 23 : Descriptive analysis of upper zone infiltrates category in 
study population (N=100) 
 
Upper zone infiltrates category Frequency Percentage 
Yes 73 73.00% 
No 27 27.00% 
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CHART 15:  horizontal  bar diagram  showing  percentage of  upper 
zone infiltrates in  study  population. 
 
Among the study population, 73 (73.00%) had upper zone infiltrates.  
Table 24: Association of diabetic status with upper zone infiltrates 
category of study population (N=100) 
Upper zone 
infiltrates 
category 
DIABETIC STATUS 
Chi 
square 
P-
value Diabetics 
(N=50) 
Non diabetics 
(N=50) 
Yes 31 (62%) 42 (84%) 
6.139 0.013 
No 19 (38%) 8 (16%) 
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CHART 16 : bar diagram showing upper zone infiltrates in chest x-
ray in diabetic  and non diabetic patients 
 
Among the diabetic, 31 (62%) were upper zone infiltrates. Among the 
non-diabetic, 42 (84%) were upper zone infiltrates.The difference in the 
proportion of diabetic status between upper zone infiltrates was 
statistically significant (P value 0.013)  
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Table 25: Descriptive analysis of middle zone infiltrates in study 
population (N=100) 
Middle zone infiltrates Frequency Percentage 
Yes(bilateral) 7 7.00% 
Yes(left) 8 8.00% 
Yes(right) 5 5.00% 
No 80 80.00% 
 
Table 26: Descriptive analysis of Middle zone infiltrates category in 
study population (N=100) 
Middle zone infiltrates category Frequency Percentage 
Yes 20 20.00% 
No 80 80.00% 
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CHART 17 : figure showing  middle zone infiltrates in chest x-ray in 
study population 
 
Among the study population, 20 (20.00%) had middle zone infiltrates.  
Table 27: Association of diabetic status with middle zone infiltrates 
category of study population (N=100) 
Middle zone 
infiltrates 
category 
DIABETIC STATUS 
Chi 
square 
P-
value Diabetics 
(N=50) 
Non diabetics 
(N=50) 
Yes 12 (24%) 8 (16%) 
1.000 0.317 
No 38 (76%) 42 (84%) 
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CHART 18: Diagram showing middle zone infiltrates in chest x-ray 
in diabetic vs. non diabetic group 
 
Among the diabetic, 12 (24%) were middle zone infiltrates. Among the 
non-diabetic, 8 (16%) were middle zone infiltrates.The difference in the 
proportion of diabetic status between middle zone infiltrates was 
statistically not significant (P value 0.317)  
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Table.28: Descriptive analysis of lower zone infiltrations in study 
population (N=100) 
Lower zone infiltrations Frequency Percentages 
Yes (bilateral) 12 12.00% 
Yes(left) 13 13.00% 
Yes(right) 9 9.00% 
No 66 66.00% 
  
Table 29: Descriptive analysis of Lower zone infiltrations category in 
study population (N=100) 
Lower zone infiltrations category Frequency Percentage 
Yes 34 34.00% 
No 66 66.00% 
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CHART 19: Pie chart showing lower zone infiltrates in study 
population 
 
Among the study population, 34 (34.00%) had lower zone infiltrates. 
Table 30: Association of diabetic status with lower zone infiltrations 
category of study population (N=100) 
Lower zone 
infiltrations 
category 
DIABETIC STATUS 
Chi 
square 
P-
value Diabetics 
(N=50)  
Non diabetics 
(N=50) 
Yes 24 (48%) 10 (20%) 
8.734 0.003 
No 26 (52%) 40 (80%) 
LOWER ZONE 
INFILTRATES, YES, 3
4%
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CHART 20: bar diagram showing lower zone infiltrates in x-ray in 
diabetic and non diabetic patients 
 
Among the diabetic, 24 (48%) were lower zone infiltrates. Among the 
non-diabetic, 10 (20%) were lower zone infiltrates.The difference in the 
proportion of diabetic status between lower zone infiltrates was 
statistically significant (P value 0.003) 
Table 31: Descriptive analysis of Sputum status at 2 months after 
initiation of treatment in study population (N=100) 
Sputum status at 2 months after 
initiation of treatment Frequency Percentage 
Positive 23 23.00% 
Negative 77 77.00% 
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Among the study population, sputum status at 2 months after initiation 
oftreatment was 23 (23.00%) had positive and 77(77.00%) had negative.  
CHART 21: Pie chart of Sputum status at 2 months after initiation of 
treatment distribution in study population (N=100) 
 
Table 32: Association of diabetic status with sputum status at 2 
months after initiation of of treatment in study population (N=100) 
Sputum status 
at 2 months 
after initiation 
of treatment 
DIABETIC STATUS 
Chi 
square 
P-
value Diabetics 
(N=50) 
Non diabetics 
(N=50) 
Positive 15 (30%) 8 (16%) 
2.767 0.096 
Negative 35 (70%) 42 (84%) 
SPUTUM 
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%
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Among the diabetic, 15 (30%) had positive, and 35 (70%) had 
negative.Among the non-diabetic, 8 (16%) had positive, and 42 (84%) 
had negative.The difference in the proportion of diabetic status between 
sputum status at 2 months was statistically not significant (P value 0.096) 
 
CHART 22: Stacked bar chart of association of diabetic status with 
sputum status at 2 months after initiation of treatment initiation of 
study population (N=100) 
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Table 33: Comparison of mean FBS across study groups (N=100) 
SPUTUM 
STATUS AT 2 
MONTHS 
AFTER 
TREATMENT 
INITIATION 
 FBS  
Mean± STD 
Mean 
difference 
95% CI 
P 
value Lower Upper 
Positive 
149.91 ± 
50.86 
18.22 -4.85 41.30 0.120 
Negative 
131.69 ± 
48.37 
 
The mean FBSof sputum status positive at 2 months was 149.91 ± 50.86 
and negative was 131.69 ± 48.37, and the mean difference (18.22) 
between two groups was statistically not significant (P value <0.120).  
Table 34: Comparison of mean PPBS across study groups (N=100) 
SPUTUM 
STATUS AT 
2  MONTHS 
I1 
 PPBS 
 Mean± STD 
Mean 
difference 
95% CI 
P 
value Lower Upper 
Positive 
228.35 ± 
90.67 34.36 -8.15 76.87 0.112 
Negative 193.99 ± 90 
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The mean PPBSof sputum status at 2 months was 228.35 ± 90.67 and 
negative was 193.99 ± 90, and the mean difference (34.36) between two 
groups was statistically not significant (P value <0.112). 
CHART 23: bar diagram showing mean FBS and PPBS  levels in 
sputum positive and negative patients 
 
Table 35: Comparison of sputum conversion rate between two 
groups 
Sputum status 
at 2 months 
after treatment 
initiation 
DIABETIC STATUS 
Chi 
square 
P-value 
Diabetics Non diabetics 
Sputum 
conversion rate  
35 (70%) 42 (84%) 
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CHART 23: horizontal  bar  diagram showing sputum conversion 
rates in diabetic and non diabetic patients 
 
The sputum conversion rate is 70 % in diabetic patients while it is 84% in 
non diabetic patients. Even though sputum conversion rates are less in 
diabetics it is not statistically significant. 
Table 36: Descriptive analysis of treatment outcomes in study 
population (N=100) 
Treatment outcomes Frequency Percentages 
Completed 91 91.00% 
Defaulter 4 4.00% 
Failure 5 5.00% 
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Among the study population, 91(91.00%) have completed the treatment, 
4 (4.00%) were defaulter the treatment, and remaining 5(5.00%) were 
treatment failures. (Table 13 & Fig 2) 
CHART 24: Pie chart of treatment outcomes distribution in study 
population (N=100) 
 
Table 37: Association of diabetic status with treatment outcomes of 
study population (N=100) 
Treatment 
outcomes 
DIABETIC STATUS Chi 
square 
P-
value Diabetics  Non diabetics 
Completed 44 (88%) 47 (94%) 
1.899 0.387 
Defaulter 2 (4%) 2 (4%) 
Failure 4 (8%) 1 (2%) 
COMPLETED, 91.00
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Among the diabetic, 44 (88%) have treatment completed, 2 (4%) were 
treatment defaulter, and 4 (8%) were treatment failure.Among the non-
diabetic, 47 (94%) have treatment completed, 2 (4%) were treatment 
defaulter, and 1 (2%) were treatment failure.The difference in the 
proportion of diabetic status between treatment outcomes was statistically 
not significant (P value 0.387)  
CHART 25: Stacked bar chart of association of diabetic status with 
treatment outcomes of study population (N=100) 
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Table 38: Descriptive analysis of drugs for diabetic mellitus in study 
population (N=50) 
Drugs for diabetic mellitus Frequency Percentage 
Biguanides 28 56.00% 
Insulin 10 20.00% 
Sulphonylureas 12 24.00% 
 
CHART 26: diagram showing percentage of patients on various anti 
diabetic medications 
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Among the diabetic population, 28 (28.00%) were receiving biguanides, 
10 (10.00%) were receiving insulin, and 12 (12.00%) were receiving 
sulphonylureas. 
Table 39: Descriptive analysis of ADR (Adverse Drug Reaction) in 
study population (N=100) 
ADR Frequency Percentage 
ADR peripheral neuropathy 28 28.00% 
Liver injury 25 25.00% 
Hypoglycemia 4 4.00% 
Back pain 11 11.00% 
Nausea vomiting 52 52.00% 
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CHART 27 : bar diagram showing frequency distribution of ADR in 
study population 
 
Among the study population, 28 (28.00%) hadperipheral neuropathy, 25 
(25.00%) had liver injury, 4 (4.00%) had hypoglycemia, 11 (11.00%) had 
back pain, and 52 (52.00%) had nausea vomiting. 
Table 40: Association of diabetic status with ADR peripheral 
neuropathy of study population (N= 100) 
ADR 
PERIPHERAL 
NEUROPATHY 
DIABETIC STATUS 
Chi 
square 
P-value 
Diabetics 
Non 
diabetics 
YES 19 (38%) 9 (18%) 
4.960 0.026 
NO 31 (62%) 41 (82%) 
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Among the diabetic, 19 (38%) had peripheral neuropathy. Among the non 
diabetic, 9 (18%) had peripheral neuropathy.The difference in the 
proportion of diabetic status between ADR peripheral neuropathy was 
statistically significant (P value 0.026) 
Table 41: Comparison of mean FBS across study groups (N=100) 
ADR 
PERIPHERAL 
NEUROPATHY 
 FBS  
Mean± STD 
Mean 
difference 
95% CI 
P 
value Lower Upper 
Yes 163.5 ± 60.26 
38.36 17.86 58.87 <0.001 
No 
125.14 ± 
39.87 
 
The mean FBSof peripheral neuropathy was 163.5 ± 60.26 and without 
peripheral neuropathy was 125.14 ± 39.87, and the mean difference 
(38.36) between two groups was statistically significant (P value <0.001).  
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Table 42: Comparison of mean PPBS across study groups (N=100) 
ADR 
PERIPHERAL 
NEUROPATHY 
 PPBS  
Mean± STD 
Mean 
difference 
95% CI 
P 
value Lower Upper 
Yes 
241.18 ± 
104.81 
54.57 15.71 93.42 0.006 
No 
186.61 ± 
80.55 
 
The mean PPBSof peripheral neuropathy was 241.18 ± 104.81 and 
without peripheral neuropathy was 186.61 ± 80.55, and the mean 
difference (54.57) between two groups was statistically significant (P 
value 0.006). 
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Table 43: Association of diabetic status with liver injury of study 
population (N=100) 
LIVER INJURY 
DIABETIC STATUS Chi 
square 
P-value 
Diabetics Non diabetics 
YES 15 (30%) 10 (20%) 
1.333 0.248 
NO 35 (70%) 40 (80%) 
 
Among the diabetic, 15 (30%) had liver injury. Among the non-diabetic, 
10 (20%) had liver injury.The difference in the proportion of diabetic 
status between liver injury was statistically not significant (P value 0.248) 
Table 44: Association of alcohol with liver injury of study population 
(N=100) 
LIVER 
INJURY 
ALCOHOL Chi 
square 
P-value 
Yes No 
Yes 18 (47.37%) 7 (11.29%) 
16.355 <0.001 
No 20 (52.63%) 55 (88.71%) 
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Among the people using alcohol, 18 (47.37%) had liver injury. Among 
the people never using alcohol 7 (11.29%) had liver injury. The 
difference in the proportion of alcohol between liver injury was 
statistically significant (P value <0.001) 
Table 45: Association of diabetic status with hypoglycemia of study 
population (N=100) 
HYPOGLYCEMIA 
DIABETIC STATUS 
Diabetics Non diabetics 
Yes 4 (8%) 0 (0%) 
No 46 (92%) 50 (100%) 
*No statistical test was applied- due to 0 subjects in the cells.  
Among the diabetic, 4 (8%) had hypoglycemia. 
Table 46: Association of diabetic status with back pain of study 
population (N=100) 
BACK PAIN 
DIABETIC STATUS Chi 
square 
P-value 
Diabetics Non diabetics 
Yes 8 (16%) 3 (6%) 
2.554 0.110 
No 42 (84%) 47 (94%) 
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Among the diabetic, 8 (16%) had back pain. Among the non-diabetic, 3 
(6%) had back pain.The difference in the proportion of diabetic status 
between back pain was statistically not significant (P value 0.110) 
Table 47: Association of diabetic status with nausea vomiting of 
study population (N=100) 
NAUSEA 
VOMITING 
DIABETIC STATUS Chi 
square 
P-value 
Diabetics Non diabetics 
Yes 16 (32%) 36 (72%) 
16.026 <0.001 
No 34 (68%) 14 (28%) 
 
Among the diabetic, 8 (16%) had back pain. Among the non-diabetic, 3 
(6%) had back pain.The difference in the proportion of diabetic status 
between nausea vomiting was statistically significant (P value <0.001) 
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DISCUSSION 
Despite  a  concurrent  increase  in  coexistence  of diabetes  and  
tuberculosis in  India, limited  data  is  available  in  south  India. The  
Union  /World  diabetes  foundation  has  acknowledged  the  need  for   
more  epidemiological  research  to  determine  TB  burden  attributed  to  
Diabetes. 
Our  study  included  newly  diagnosed  diabetic  patients  with  
sputum  positive  pulmonary  tuberculosis. In  previous  literature  a  wide  
prevalence  of 1.9- 35%  of diabetes  has  been  reported  in active  TB  
patients. Studies  from Indonesia  and  Tanzania  has  reported   73%  and   
61%  of  newly  diagnosed diabetes  among  TB  patients   respectively. 
This  confers  the  need  of  expanded  medical  attention  in  screening  of  
TB  patients  for  diabetes  and its  effective  management. 
Our  results  showed  that  diabetic  patients  were  more  likely  to  
be  male   and  of  older  age  group  when  compared  to  non  diabetics. 
In diabetic patients   the  proportion  of   TB  appears  to  increase  with  
age. Case  series by  Deshmukh  et  al 30 with  138  TB – DM  patients  
revealed  that  82.6%  of  the  study  population  was  above  45 years  
and  there  was  a  male   preponderance. Patients   were  having  risk  
factors  of  smoking , alcohol  
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consumption  and  pan  chewing. A  multicentre  case-control  study  was 
conducted  in  Guinee ,  Guinea  Bissau  and  Gambia  in  West  Africa ,  
from January  1999  to  March  2001,  wherein  846  newly  detected  
sputum   smear positive  cases , 702  household  controls  and  828  
community  controls  were recruited  in  the  three  countries37. It  showed   
smoking , alcohol  and  other  environmental  factors  resulted  in  
development  of  tuberculosis. 
Analysing  symptoms  associated  with  tuberculosis , we  found  
that dyspnoea  , hemoptysis  and  chest  pain  were  more  among  
diabetics  when compared  to  non  diabetics. Weight  loss   is  thought  to  
be  more  frequent  in Tb  with  diabetes. However  in  our  study  weight  
loss  was  seen  more  in  non  diabetic  patients. In  a  study  by  
Alisjahbana  et  al  42it  showed  more weight  loss  among  diabetic  
patients. Few  authors  have  suggested  that  there is  not  much  
difference  in  clinical  presentation  of  Tb  among  diabetics  and non  
diabetics. Low  grade  fever  and  productive  cough  were  the  most  
common  symptoms  and  were  observed  with  almost  equal  frequency  
in both  groups. 
In  our  study  we  observed  higher  rates  of  sputum  3+  positive  
and  sputum  2+  positive  patients  among  diabetics. Study  by  
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Alisjahbana  et  al   reported higher  frequency  of  sputum  negative  
smears  in  diabetic  patients. Few studies  show  no  association  between  
sputum  positivity  and  diabetic  status. Another  study  looked  at  the  
effect  of  diabetes  on  the presentation  of  pulmonary  TB  patients. 46  
Records  of  692  smear-positive  pulmonary  TB  patients  admitted  to  a  
referral  hospital  in  Riyadh ,  Saudi Arabia , were  reviewed  
retrospectively. The  baseline  characteristics  of  187 patients  with  DM  
(TB-DM group)  were  compared  to  505  patients  without  DM  (TB 
group). In  the  TB-DM  group , 65.2 %  of  the  patients  had  numerous  
( >1  bacillus  per  oil  immersion  field)  AFB   on  the  sputum smear  
examination  compared  to 54.1%  in  the  control  group. They  
established  that  TB-DM  patients  have  an  elevated  pre-treatment  
bacillary  load.DM  was  an  independent  risk  factor  associated  with  
numerous  AFB on  sputum  smear  examination. They  explained  that  
the  immune  suppression  induced  by  DM  could  be  responsible  for  
the  high  bacillary load  in  TB  patients  with  DM. 
In  our  study  we  notice  that  diabetic  patients  had  more   
cavities  in  chest  X-Ray. In  our  study  diabetic  patients  had  more  of 
infiltrates  in  the  lower  zone  when  compared  to non  diabetic  patients. 
Comparative  studies  of  chest  X-ray  findings  in  diabetics  with  
tuberculosis have  yielded  contrasting  results. In  a  lot  of  published  
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articles  chest radiograph  images  from  patients  have  been  described  
as  ‘atypical’. This  is because  they  often   involve  the  lower  lung  
fields,  mostly  with  cavities. 
The  largest  study  done  by  Perenz-Guzman  et  al  in  Mexico38. 
It  compared  the  radiological  findings  of  pulmonary  tuberculosis  in  
192  diabetic  patients  with  a  control  group  of  patients  with  
pulmonary  tuberculosis   alone. It  showed  that  both  the  groups  had  a  
similar  progression  time  of tuberculosis ,  around  two  years. In  this  
study  the  TB-DM  patients  were   older (51.3 ± 0.9 vs. TB  group  44.9 
± 1.8 years).They  had  a  lower  frequency of  upper  (17%  vs.  56%) , 
and  an  higher  frequency  of  lower  (19%  vs. 7%) and  upper  and  
lower  (64%  vs.  36%)  lung  field  lesions. TB-DM  patients developed  
cavitations  (82%  vs.  59%) more  commonly  in  the  lower  lung fields  
(29%  vs.  3%). Cavities  were  more  often  multiple  in  the  TB-DM 
patients  (25%  vs.  2%). Statistical  analysis   showed  that  being  a  
diabetic patient  was  the  most  important  factor  determining  lower  
lung  field  lesions and  cavities. Thus  this  study , along  with  earlier  
studies  confirmed   that  chest  radiograph  images  considerably  sally  
forth  from  the  typical  presentation. Other  authors  have  been  unable  
to  find  differences  in  the  chest  x-ray  patterns  of  pulmonary   
tuberculosis  in  diabetics  and  non- diabetic  patients. 
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The  sputum  status  at  2  month  after  initiation  of  treatment  
was  studied.It  showed  higher  rates  of  sputum  positive  patients  with  
low  levels of  sputum  conversion  among  diabetic  patients  when  
compared  to  non  diabetic  patients. Few  studies  did  not  reveal  any  
relation  between   sputum  conversion  rates  and  diabetic  status. Poor  
diabetic  control  probably  lead  to sputum   positive  status  at  the  end  
of  intensive  phase. Patients  with  higher   value  of  blood  sugar  at  the  
beginning  of  treatment  tend  to  remain  sputum positive  after  
intensive  phase, according  to  our  study. In  a  study  from Turkey 36, 
the  bacteriological  profile  of  737  patients  from  2000  to  2005  with  
pulmonary  TB  was  studied. Three  hundred  six  ( 193  men  and  113  
women )  patients  newly  diagnosed  with  pulmonary  TB  and  HIV  
negative  were  evaluated. Factors  associated  with  both  sputum  smear  
and  culture conversion  time  were  studied. It  was  found  that  patients  
with  DM ,  cavitary  disease  and  radio logically  extensive  disease  tend  
to  have  longer sputum  smear  and  culture  conversion  time  than  the  
other  groups. 
In  our  study  we  had  very  few  defaulters  and  failures. The  
failures  were  all  diabetic  patients  but  it  was  not  statistically  
significant.  There  is  scarcity  of  data  regarding  the  outcome  of  
treatment  of  TB patients  with  coexisting  diabetes. Some  studies  
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suggest  adverse  effects  of  hyperglycemia   on  the  treatment  outcome  
of  TB  patients. There  is  an  increased  rate  of  failures ,  deaths ,  
defaults  and  relapse. Mortality  rates  in such  patients  are  stated  to  be  
quite  high  when  compared  to  non-diabetic  pulmonary  TB  patients. 
Studies   have  also  pointed  out  that ,  In  well- controlled  diabetes  the 
course  of  pulmonary  tuberculosis  is  not  different from  that  in  
patients  without  diabetes. 
In  our  study  the  incidence  of  adverse  reactions  to  anti 
tuberculosis  drugs  were  variable. Diabetics  had  more   incidences  of  
peripheral  neuropathy  and  liver  injury. Presence   of  diabetes  
influences   the adverse  drug   reactions. This  is  mostly  attributed  to  
the  anti  diabetic medications43-46. No  large  studies  exist  regarding  
evaluation  of  adverse  drug  reactions  to  ATT  in  diabetic  patients. 
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CONCLUSION 
 
 All  patients  with  pulmonary  tuberculosis  should  be  screened  
for  diabetes  mellitus   and  should   be  effectively  treated  for  
the  same. 
 Pulmonary  Tuberculosis  patients   who  have  diabetes  tend  to  
have higher  sputum  positivity  rates  and  delayed   sputum  
conversion  if  glycemic  levels  are  poorly controlled 
 Patients  with  coexisting   pulmonary   tuberculosis  and  diabetes  
mellitus  have  atypical  presentations. Chest  radiographs  of  such  
patients  show  multiple  cavitations  with  predominant  lower  
lobe  involvement 
 The  rates  of  treatment  failures   and  treatment  outcomes  are   
adversely   affected   by  the  presence  of  diabetes. 
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SUMMARY 
Our  study  conducted  with  a  sample  size  of  100  patients  
sputum  positive  tuberculosis  in our  hospital  from  January- 2016   to  
June  2017.50  patients  with  newly  detected  diabetes  mellitus  and  50  
patients without  diabetes  were compared  and  studied. There  was  male  
preponderance. The  mean  age  group  of  pulmonary  tuberculosis with  
diabetes  was  higher  when  compared  to  non  diabetics. 
              Symptom   analysis  showed   that   pulmonary  tuberculosis  
with  diabetes   had variable  symptoms  and  signs  with  atypical  
presentations. Patients  with  diabetes  and TB  had  more  of  hemoptysis  
chest pain and dyspnoea.  The  rate  of  sputum  positivity  were  seen   
more  in  diabetic  patients. The   blood  sugar  values  were  directly  
proportional  to the  sputum positivity  rates. There  was  delayed  sputum  
conversion  in  TB   patients   with  associated   diabetes  mellitus. 
            Chest  radiographs   of   pulmonary   tuberculosis   patients   
having  diabetes   showed   cavitations   mainly   involving  the  lower  
lobes. The  treatment  failure  rates  were  high  among   patients  with  
diabetes  and pulmonary  tuberculosis. The pattern  of  adverse drug  
reactions  were  more specific  for  patients  with TB  and  DM  
coinfection 
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1 1 44 FEMALE NO NO NO 240 312 3+ CAVITY NO NO YES (BILATERAL) POSITIVE COMPLETED YES YES YES NO YES YES
2 1 56 MALE YES YES NO 140 210 2+ NO YES(LEFT) NO NO NEGATIVE COMPLETED YES NO NO YES NO NO
3 1 45 MALE YES YES NO 142 276 2+ NO YES(BILATERAL) NO NO NEGATIVE COMPLETED YES NO YES YES YES NO
4 1 72 MALE YES YES NO 178 319 3+ NO NO NO YES(LEFT) NEGATIVE DEFAULTER YES NO NO NO NO NO
5 1 54 MALE NO YES NO 159 263 2+ CAVITY YES(BILATERAL) NO NO POSITIVE COMPLETED YES YES NO YES YES YES
6 1 48 FEMALE NO NO NO 162 294 2+ NO YES(LEFT) NO NO NEGATIVE COMPLETED YES NO NO NO NO NO
7 1 38 MALE NO YES NO 132 216 2+ NO YES(RIGHT) NO NO NEGATIVE DEFAULTER YES NO YES NO YES NO
8 1 63 FEMALE NO NO NO 189 315 3+ PNEUMOTHORAX NO YES(LEFT) YES(LEFT) NEGATIVE COMPLETED YES YES YES NO NO NO
9 1 70 MALE NO YES NO 151 218 2+ NO NO NO YES(LEFT) NEGATIVE COMPLETED NO YES NO YES YES NO
10 1 49 MALE YES NO NO 143 253 2+ NO YES(BILATERAL) YES(BILATERAL) YES(BILATERAL) POSITIVE FAILURE YES YES YES NO YES NO
11 1 48 MALE YES YES NO 212 359 3+ CAVITY YES(BILATERAL) YES(BILATERAL) YES(BILATERAL) POSITIVE COMPLETED YES YES NO YES YES YES
12 1 42 FEMALE NO NO NO 190 278 2+ CAVITY YES(LEFT) NO NO NEGATIVE COMPLETED YES YES NO YES NO YES
13 1 40 FEMALE NO NO NO 278 398 3+ CAVITY NO NO YES(BILATERAL) NEGATIVE COMPLETED YES YES YES NO YES YES
14 1 52 FEMALE NO NO YES 245 402 3+ PNEUMOTHORAX YES(BILATERAL) YES(BILATERAL) YES(BILATERAL) POSITIVE FAILURE YES YES YES YES YES YES
15 1 51 MALE YES YES NO 196 368 3+ CAVITY NO NO YES(LEFT) NEGATIVE COMPLETED YES YES YES NO YES YES
16 1 47 MALE YES YES NO 204 324 3+ NO YES(BILATERAL) YES(BILATERAL) YES(BILATERAL) POSITIVE COMPLETED YES NO YES YES YES NO
17 1 56 MALE YES YES NO 179 246 3+ CAVITY NO NO YES(LEFT) NEGATIVE COMPLETED NO YES NO YES YES YES
18 1 64 MALE YES YES NO 137 198 1+ NO YES(LEFT) NO NO POSITIVE COMPLETED YES NO NO NO NO NO
19 1 49 MALE YES YES NO 129 232 1+ CAVITY YES(LEFT) NO NO NEGATIVE COMPLETED YES YES YES YES YES NO
20 1 43 FEMALE NO NO NO 158 269 2+ NO NO NO YES(RIGHT) NEGATIVE COMPLETED YES NO NO NO NO NO
21 1 42 FEMALE NO NO NO 149 312 2+ CAVITY YES(LEFT) NO NO NEGATIVE COMPLETED NO YES YES YES YES YES
22 1 44 MALE YES NO NO 186 257 2+ NO YES(BILATERAL) NO NO NEGATIVE COMPLETED YES NO NO YES NO NO
23 1 41 MALE YES YES NO 175 298 2+ CAVITY YES(LEFT) NO NO POSITIVE COMPLETED YES YES NO YES YES YES
24 1 47 MALE NO YES NO 141 231 1+ NO YES(LEFT) NO NO NEGATIVE COMPLETED NO NO NO NO NO NO
25 1 45 MALE YES NO NO 169 251 2+ PLEURAL EFFUSION YES(RIGHT) NO NO NEGATIVE COMPLETED YES NO NO YES NO NO
26 1 49 FEMALE YES NO NO 192 237 2+ NO YES(LEFT) NO NO POSITIVE COMPLETED YES NO YES NO YES NO
27 1 51 FEMALE NO NO NO 201 273 2+ NO NO NO YES(RIGHT) NEGATIVE COMPLETED NO YES YES YES YES NO
28 1 69 FEMALE NO NO YES 183 254 2+ NO NO YES(LEFT) YES(LEFT) POSITIVE COMPLETED NO YES NO NO NO NO
29 1 50 MALE YES YES NO 146 267 2+ NO YES(LEFT) NO NO NEGATIVE COMPLETED NO NO YES NO YES NO
30 1 48 MALE NO NO NO 195 329 2+ CAVITY NO NO YES(RIGHT) NEGATIVE COMPLETED YES YES YES NO YES YES
31 1 46 MALE YES YES NO 136 214 1+ NO YES(BILATERAL) NO NO POSITIVE COMPLETED YES NO YES NO YES NO
32 1 42 MALE YES YES NO 167 243 2+ NO NO NO YES(RIGHT) NEGATIVE COMPLETED YES NO YES NO YES YES
33 1 53 MALE NO NO NO 234 398 3+ CAVITY YES(RIGHT) NO NO NEGATIVE COMPLETED YES YES YES YES YES YES
34 1 50 MALE NO YES NO 246 364 2+ NO NO NO YES(LEFT) NEGATIVE COMPLETED NO YES YES YES YES YES
35 1 39 FEMALE NO NO NO 194 299 2+ NO YES(BILATERAL) NO NO NEGATIVE COMPLETED YES NO YES YES YES NO
36 1 47 FEMALE NO NO NO 177 278 2+ PLEURAL EFFUSION NO NO YES(LEFT) NEGATIVE COMPLETED YES NO YES NO YES NO
37 1 44 FEMALE NO NO NO 132 205 1+ NO YES(LEFT) YES(LEFT) NO NEGATIVE COMPLETED YES NO YES YES YES NO
38 1 62 FEMALE NO NO YES 194 329 2+ CAVITY YES(RIGHT) YES(RIGHT) NO NEGATIVE COMPLETED NO YES YES YES YES YES
39 1 48 MALE YES YES NO 187 345 3+ CAVITY NO YES(LEFT) YES(LEFT) POSITIVE FAILURE NO YES YES NO YES YES
40 1 72 FEMALE NO NO YES 179 297 2+ NO YES(BILATERAL) YES(BILATERAL) YES(BILATERAL) POSITIVE COMPLETED YES NO YES NO YES NO
41 1 68 MALE YES YES NO 214 378 3+ CAVITY YES(RIGHT) NO NO NEGATIVE COMPLETED NO YES YES NO YES YES
42 1 51 FEMALE NO NO NO 198 342 2+ CAVITY YES(LEFT) NO NO NEGATIVE COMPLETED NO YES YES NO YES NO
43 1 48 FEMALE NO NO NO 178 267 2+ NO YES(RIGHT) NO NO NEGATIVE COMPLETED YES NO YES NO YES NO
44 1 46 FEMALE NO NO NO 149 194 1+ NO YES(RIGHT) YES(RIGHT) NO NEGATIVE COMPLETED YES NO NO NO YES NO
45 1 61 MALE YES YES NO 198 308 3+ CAVITY YES(RIGHT) NO NO NEGATIVE COMPLETED NO YES YES NO YES YES
46 1 65 FEMALE NO NO YES 176 268 2+ CAVITY NO NO YES(LEFT) NEGATIVE COMPLETED NO YES NO YES YES YES
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47 1 52 FEMALE NO NO NO 182 219 2+ NO YES(LEFT) NO NO NEGATIVE COMPLETED YES NO NO YES YES NO
48 1 54 FEMALE NO NO NO 165 289 3+ CAVITY NO YES(RIGHT) YES(RIGHT) POSITIVE FAILURE NO YES NO NO YES YES
49 1 48 MALE YES NO NO 148 212 2+ NO NO NO YES(RIGHT) POSITIVE COMPLETED YES YES NO NO YES YES
50 1 42 FEMALE NO NO NO 184 245 2+ NO NO NO YES(BILATERAL) NEGATIVE COMPLETED NO NO NO NO YES NO
51 2 43 MALE NO YES NO 100 124 2+ NO YES(LEFT) NO NO NEGATIVE COMPLETED YES NO YES YES YES NO
52 2 30 FEMALE NO NO NO 96 126 2+ CAVITY YES(BILATERAL) NO NO POSITIVE COMPLETED YES YES YES YES YES YES
53 2 32 MALE YES YES NN 84 132 1+ NO YES(LEFT) NO NO NEGATIVE COMPLETED NO NO NO NO YES NO
54 2 44 FEMALE NO NO YES 108 132 1+ NO YES(RIGHT) NO NO NEGATIVE COMPLETED NO NO YES YES YES NO
55 2 45 MALE YES YES NO 86 128 1+ NO YES(LEFT) NO NO NEGATIVE COMPLETED NO NO YES YES YES NO
56 2 34 MALE NO YES NO 92 120 1+ NO NO NO YES(LEFT) NEGATIVE COMPLETED YES NO YES YES NO NO
57 2 38 MALE NO YES NO 107 120 2+ CAVITY NO NO YES(RIGHT) POSITIVE COMPLETED YES YES NO YES YES YES
58 2 39 FEMALE NO NO NO 100 130 2+ NO YES(RIGHT) NO NO NEGATIVE COMPLETED YES NO YES YES YES NO
59 2 21 MALE NO NO NO 101 120 3+ NO YES(BILATERAL) YES(BILATERAL) YES(BILATERAL) POSITIVE COMPLETED YES NO YES YES YES NO
60 2 31 MALE NO YES NO 94 118 1+ NO YES(LEFT) NO NO NEGATIVE COMPLETED NO NO YES NO NO NO
61 2 24 MALE NO NO NO 87 120 2+ NO YES(RIGHT) YES(RIGHT) NO NEGATIVE DEFAULTER NO NO YES YES YES NO
62 2 36 FEMALE NO NO NO 90 115 1+ NO YES(LEFT) NO NO NEGATIVE COMPLETED NO YES NO NO NO NO
63 2 32 MALE NO YES NO 92 119 1+ NO YES(LEFT) NO NO NEGATIVE COMPLETED YES NO YES YES YES NO
64 2 37 MALE NO YES YES 96 120 1+ NO YES(RIGHT) NO NO NEGATIVE COMPLETED NO NO YES YES YES NO
65 2 39 MALE NO YES NO 83 109 2+ NO YES(BILATERAL) NO NO NEGATIVE COMPLETED NO NO NO NO NO NO
66 2 48 FEMALE NO NO NO 88 122 2+ CAVITY NO NO YES(LEFT) POSITIVE FAILURE YES YES YES YES YES YES
67 2 43 MALE YES NO NO 99 126 1+ NO YES(LEFT) NO NO NEGATIVE COMPLETED NO NO YES YES YES NO
68 2 46 FEMALE NO NO YES 108 139 1+ CAVITY NO NO YES(BILATERAL) NEGATIVE COMPLETED YES YES NO YES YES YES
69 2 28 MALE NO NO NO 102 116 2+ NO YES(LEFT) YES(LEFT) NO NEGATIVE COMPLETED NO NO YES YES YES NO
70 2 31 MALE NO YES NO 92 134 3+ CAVITY YES(BILATERAL) YES(BILATERAL) YES(BILATERAL) POSITIVE COMPLETED YES YES YES YES YES YES
71 2 34 MALE YES YES NO 95 129 2+ NO YES(RIGHT) NO NO NEGATIVE COMPLETED NO NO NO YES YES NO
72 2 29 MALE NO NO NO 85 117 2+ NO YES(RIGHT) NO NO NEGATIVE COMPLETED NO NO YES NO YES NO
73 2 30 MALE YES YES NO 80 119 3+ NO YES(LEFT) NO NO POSITIVE COMPLETED YES YES YES YES YES YES
74 2 34 FEMALE NO NO NO 87 110 2+ NO NO NO YES(BILATERAL) NEGATIVE COMPLETED NO NO NO NO NO NO
75 2 31 MALE YES YES NO 100 110 2+ NO YES(LEFT) NO NO NEGATIVE DEFAULTER NO NO YES YES YES NO
76 2 38 FEMALE NO NO NO 81 130 1+ CAVITY YES(BILATERAL) NO NO NEGATIVE COMPLETED YES YES YES YES YES YES
77 2 41 MALE YES NO NO 84 120 1+ NO NO YES(LEFT) YES(LEFT) NEGATIVE COMPLETED NO NO YES YES YES NO
78 2 42 MALE YES YES NO 96 114 2+ NO YES(RIGHT) NO NO NEGATIVE COMPLETED YES YES NO YES YES NO
79 2 23 MALE NO NO NO 94 118 3+ NO YES(RIGHT) NO NO NEGATIVE COMPLETED NO NO YES YES YES NO
80 2 46 FEMALE NO NO YES 109 128 2+ NO YES(LEFT) YES(LEFT) NO NEGATIVE COMPLETED NO NO YES YES YES NO
81 2 19 MALE NO NO NO 92 108 1+ NO YES(LEFT) NO NO NEGATIVE COMPLETED NO NO YES NO NO NO
82 2 22 MALE NO NO NO 93 136 1+ NO YES(RIGHT) NO NO NEGATIVE COMPLETED YES NO NO YES YES NO
83 2 42 MALE YES YES NO 90 129 2+ NO NO NO YES(RIGHT) NEGATIVE COMPLETED NO NO YES NO YES NO
84 2 43 FEMALE NO NO NO 87 122 2+ CAVITY YES(LEFT) NO NO POSITIVE COMPLETED YES YES YES YES YES YES
85 2 25 MALE NO YES NO 88 110 1+ NO YES(RIGHT) NO NO NEGATIVE COMPLETED NO NO YES YES YES NO
86 2 26 FEMALE NO NO NO 84 127 1+ NO YES(RIGHT) NO NO NEGATIVE COMPLETED NO NO YES YES YES NO
87 2 23 FEMALE NO NO NO 83 112 2+ NO YES(BILATERAL) NO NO NEGATIVE COMPLETED NO NO YES NO NO NO
88 2 34 MALE YES YES NO 80 118 2+ NO YES(LEFT) NO NO NEGATIVE COMPLETED NO YES YES YES YES NO
89 2 33 FEMALE NO NO NO 100 109 3+ NO YES(LEFT) NO NO NEGATIVE COMPLETED NO NO NO YES YES NO
90 2 37 FEMALE NO NO NO 86 102 2+ PLEURAL EFFUSION YES(LEFT) NO NO NEGATIVE COMPLETED NO NO NO YES YES NO
91 2 40 MALE YES NO NO 87 104 1+ NO YES(RIGHT) NO NO NEGATIVE COMPLETED NO NO NO YES YES NO
92 2 31 FEMALE NO NO NO 98 100 1+ NO YES(LEFT) NO NO NEGATIVE COMPLETED NO NO NO YES YES NO
93 2 32 MALE NO NO NO 92 132 2+ CAVITY NO YES(RIGHT) YES(RIGHT) POSITIVE COMPLETED YES YES YES NO YES YES
94 2 26 FEMALE NO NO NO 99 128 2+ NO YES(LEFT) NO NO NEGATIVE COMPLETED NO NO YES YES YES NO
95 2 31 FEMALE NO NO NO 104 119 2+ NO YES(LEFT) NO NO NEGATIVE COMPLETED NO NO YES YES YES NO
96 2 30 MALE YES NO NO 100 130 1+ CAVITY YES(RIGHT) NO NO NEGATIVE COMPLETED YES YES YES NO NO YES
97 2 33 FEMALE NO NO NO 92 122 1+ NO YES(RIGHT) NO NO NEGATIVE COMPLETED NO NO YES YES YES NO
98 2 35 FEMALE NO NO NO 93 100 1+ CAVITY YES(RIGHT) NO NO NEGATIVE COMPLETED YES YES YES YES YES YES
99 2 40 FEMALE NO NO NO 103 139 2+ NO YES(RIGHT) NO NO NEGATIVE COMPLETED YES NO YES NO YES NO
100 2 39 FEMALE NO NO NO 82 124 2+ NO YES(LEFT) YES(LEFT) NO NEGATIVE COMPLETED NO NO YES YES YES NO
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